Skip to main content
. 2022 Dec 15;2022:3124122. doi: 10.1155/2022/3124122

Figure 4.

Figure 4

(a) Differences in TIDE scores across the three subtypes. (b) Differences in T-cell dysfunction scores across the three subtypes. (c) Differences in T-cell rejection scores across the three subtypes. The box plots demonstrate the estimated IC50 values for gemcitabine (d), erlotinib (e), and 5-Fu (f).